Yihua Gu

5.9k total citations · 5 hit papers
58 papers, 3.8k citations indexed

About

Yihua Gu is a scholar working on Immunology, Molecular Biology and Dermatology. According to data from OpenAlex, Yihua Gu has authored 58 papers receiving a total of 3.8k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Immunology, 21 papers in Molecular Biology and 19 papers in Dermatology. Recurrent topics in Yihua Gu's work include Psoriasis: Treatment and Pathogenesis (14 papers), Dermatology and Skin Diseases (13 papers) and Sperm and Testicular Function (9 papers). Yihua Gu is often cited by papers focused on Psoriasis: Treatment and Pathogenesis (14 papers), Dermatology and Skin Diseases (13 papers) and Sperm and Testicular Function (9 papers). Yihua Gu collaborates with scholars based in United States, China and Canada. Yihua Gu's co-authors include Kim Papp, Kenneth B. Gordon, Martin M. Okun, Bruce Strober, Alan Menter, Craig L. Leonardi, Richard G. Langley, Alexa B. Kimball, Yves Poulin and Stephen K. Tyring and has published in prestigious journals such as The Lancet, Journal of Biological Chemistry and Annals of Internal Medicine.

In The Last Decade

Yihua Gu

57 papers receiving 3.7k citations

Hit Papers

Adalimumab therapy for moderate to severe psoriasis: A ra... 2007 2026 2013 2019 2007 2018 2021 2012 2019 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial
    2007 695 citations Alan Menter, Stephen K. Tyring et al. Journal of the American Academy of Dermatology profile →
  2. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials
    2018 452 citations Kenneth B. Gordon, Bruce Strober et al. The Lancet profile →
  3. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials
    2021 350 citations Emma Guttman‐Yassky, Henrique D. Teixeira et al. The Lancet profile →
  4. Adalimumab for the Treatment of Moderate to Severe Hidradenitis Suppurativa
    2012 305 citations Alexa B. Kimball, Francisco A. Kerdel et al. Annals of Internal Medicine profile →
  5. Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial
    2019 255 citations Emma Guttman‐Yassky, Diamant Thaçi et al. Journal of Allergy and Clinical Immunology profile →

Peers

Yihua Gu
Yayoi Tada Japan
Paul Klekotka United States
Julien Sénéschal France
J.‐P. Ortonne France
C. Papavassilis Germany
Nicoletta Cassano Italy
G Stingl Austria
Wolf‐Dietrich Döcke Germany
Kristine Nograles United States
Robert Dawe United Kingdom
Yayoi Tada Japan
Yihua Gu
Citations per year, relative to Yihua Gu Yihua Gu (= 1×) peers Yayoi Tada

Countries citing papers authored by Yihua Gu

Since Specialization
Citations

This map shows the geographic impact of Yihua Gu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yihua Gu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yihua Gu more than expected).

Fields of papers citing papers by Yihua Gu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yihua Gu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yihua Gu. The network helps show where Yihua Gu may publish in the future.

Co-authorship network of co-authors of Yihua Gu

This figure shows the co-authorship network connecting the top 25 collaborators of Yihua Gu. A scholar is included among the top collaborators of Yihua Gu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yihua Gu. Yihua Gu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Li, Yan, Jianan Tang, Min-Min Hua, et al.. (2021). Regulation of the mammalian maternal-to-embryonic transition by eukaryotic translation initiation factor 4E. Development. 148(12). 12 indexed citations
2.
Zhan, Tianyu, Lu Cui, Ziqian Geng, et al.. (2021). A practical response adaptive block randomization (RABR) design with analytic type I error protection. Statistics in Medicine. 40(23). 4947–4960. 1 indexed citations
3.
Wu, Bin, Haiyan Dong, Liang Chen, et al.. (2021). Effects of low lead exposure on sperm quality and sperm DNA methylation in adult men. Cell & Bioscience. 11(1). 150–150. 13 indexed citations
4.
Meng, Qingyang, et al.. (2021). Regulation of dynamin-related protein 1 (DRP1) levels modulates myoblast atrophy induced by C26 colon cancer-conditioned medium. Translational Cancer Research. 10(6). 3020–3032. 3 indexed citations
5.
Gu, Yihua, Lei Shen, Jun Han, et al.. (2021). Phosphorylation of Dynamin-Related Protein 1 (DRP1) Regulates Mitochondrial Dynamics and Skeletal Muscle Wasting in Cancer Cachexia. Frontiers in Cell and Developmental Biology. 9. 673618–673618. 23 indexed citations
6.
Guttman‐Yassky, Emma, Diamant Thaçi, Aileen L. Pangan, et al.. (2019). Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial. Journal of Allergy and Clinical Immunology. 145(3). 877–884. 255 indexed citations breakdown →
7.
Reich, Kristian, Melinda Gooderham, Diamant Thaçi, et al.. (2019). Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial. The Lancet. 394(10198). 576–586. 219 indexed citations
8.
Gordon, Kenneth B., Bruce Strober, Mark Lebwohl, et al.. (2018). EFFICACY AND SAFETY OF RISANKIZUMAB: RESULTS FROM TWO DOUBLE-BLIND, PLACEBO- AND USTEKINUMAB-CONTROLLED, PHASE 3 TRIALS IN MODERATE-TO-SEVERE PLAQUE PSORIASIS. 98. 10 indexed citations
9.
Zouboulis, Christos C., Martin M. Okun, Errol P. Prens, et al.. (2018). Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa/acne inversa: 3-year results of a phase 3 open-label extension study. Journal of the American Academy of Dermatology. 80(1). 60–69.e2. 136 indexed citations
10.
Elewski, Boni E., Martin M. Okun, Kim Papp, et al.. (2017). Adalimumab for nail psoriasis: Efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trial. Journal of the American Academy of Dermatology. 78(1). 90–99.e1. 68 indexed citations
11.
Xin, Aijie, Li Cheng, Hua Diao, et al.. (2016). Lectin binding of human sperm associates with DEFB126 mutation and serves as a potential biomarker for subfertility. Scientific Reports. 6(1). 20249–20249. 23 indexed citations
12.
Poulin, Yves, et al.. (2014). Health-Related Quality of Life Worsens Disproportionately to Objective Signs of Psoriasis After Withdrawal of Adalimumab Therapy. Dermatology and Therapy. 4(1). 33–42. 12 indexed citations
13.
Xu, Yan, Miao Liu, Yihua Gu, et al.. (2014). cDNA cloning and localization of Sp3111 (also called Ms4a14 ) in the rat testis. Reproduction. 148(1). 81–86. 4 indexed citations
14.
Xin, Aijie, Li Cheng, Hua Diao, et al.. (2014). Comprehensive profiling of accessible surface glycans of mammalian sperm using a lectin microarray. Clinical Proteomics. 11(1). 10–10. 27 indexed citations
15.
Liu, Haiyan, Heguo Yu, Yihua Gu, et al.. (2012). Human beta-defensin DEFB126 is capable of inhibiting LPS-mediated inflammation. Applied Microbiology and Biotechnology. 97(8). 3395–3408. 22 indexed citations
16.
Kimball, Alexa B., Francisco A. Kerdel, David R. Adams, et al.. (2012). Adalimumab for the Treatment of Moderate to Severe Hidradenitis Suppurativa. Annals of Internal Medicine. 7 indexed citations
17.
Leonardi, Craig L., Kim Papp, Bruce Strober, et al.. (2011). The Long-Term Safety of Adalimumab Treatment in Moderate to Severe Psoriasis. American Journal of Clinical Dermatology. 12(5). 321–337. 58 indexed citations
18.
Gordon, Kenneth B., Richard G. Langley, Alice B. Gottlieb, et al.. (2011). A Phase III, Randomized, Controlled Trial of the Fully Human IL-12/23 mAb Briakinumab in Moderate-to-Severe Psoriasis. Journal of Investigative Dermatology. 132(2). 304–314. 139 indexed citations
19.
Menter, Alan, Kenneth B. Gordon, Craig L. Leonardi, Yihua Gu, & Orin M. Goldblum. (2010). Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis. Journal of the American Academy of Dermatology. 63(3). 448–456. 131 indexed citations
20.
Block, Stan L., Mary Cifaldi, Yihua Gu, & Maria Paris. (2005). A comparison of 5 days of therapy with cefdinir or azithromycin in children with acute otitis media: A multicenter, prospective, single-blind study. Clinical Therapeutics. 27(6). 786–794. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yayoi Tada Breakdown of academic impact, for papers by Paul Klekotka Breakdown of academic impact, for papers by Julien Sénéschal Breakdown of academic impact, for papers by J.‐P. Ortonne Breakdown of academic impact, for papers by C. Papavassilis Breakdown of academic impact, for papers by Nicoletta Cassano Breakdown of academic impact, for papers by G Stingl Breakdown of academic impact, for papers by Wolf‐Dietrich Döcke Breakdown of academic impact, for papers by Kristine Nograles Breakdown of academic impact, for papers by Robert Dawe
Rankless by CCL
2026